Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
BioCryst Japan to First Focus on Orladeyo Promotion, Eager to Set Up Own Sales Team: Local Head
After establishing a Japanese subsidiary last year, BioCryst Pharmaceuticals intends to hone in on detailing activities for its hereditary angioedema (HAE) drug Orladeyo (berotralstat) in the market, while exploring the launch of an in-house sales structure. The company’s Japan general…
To read the full story
Related Article
- Torii, BioCryst Revise Deal for HAE Drug Orladeyo in Japan
December 1, 2023
- Torii Acquires Japan Marketing Rights to BioCryst’s HAE Treatment
November 6, 2019
BUSINESS
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
- Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025
- Oncolys’ Oncolytic Virus Telomelysin Gets Orphan Status in Japan
December 15, 2025
- Radicut Suspension Approved in South Korea for ALS
December 15, 2025
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…